Clinical Trial Update: Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating lapatinib ditosylate plus trastuzumab, paclitaxel, and surgery for HER2-positive breast cancer completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Stage Iiia Breast Cancer

Drugs mentioned

• Lapatinib Ditosylate (lapatinib ditosylate)
• PACLITAXEL (PACLITAXEL)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: HER2-positive Breast Cancer, Stage II Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-09-11